The Cooper Companies, Inc. COO
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
The Cooper Companies, Inc. is a global medical device company focused on vision care and women’s health. The company operates primarily through two business units: CooperVision and CooperSurgical. CooperVision develops and manufactures contact lenses, including toric, multifocal, spherical, and myopia management lenses, while CooperSurgical provides fertility, reproductive health, and gynecological medical devices and services. The company operates within the broader healthcare, medical technology, and specialty medical products industries, with revenue driven largely by recurring demand for disposable contact lenses and fertility-related products and procedures.
The company serves eye care professionals, fertility clinics, hospitals, surgical centers, and healthcare providers across developed and emerging markets. A key strategic advantage is its diversified exposure to both vision care and women’s health, including strong positions in specialty contact lenses and fertility treatment technologies. Founded in 1958, Cooper evolved from a diversified healthcare holding company into a focused medical technology enterprise through acquisitions, divestitures, and expansion into global healthcare markets. The company significantly expanded its women’s health business through acquisitions including Origio, LifeGlobal, and Generate Life Sciences, while continuing to build scale in contact lenses through manufacturing and product innovation.
Business Operations
The company reports operations through two primary segments: CooperVision and CooperSurgical. CooperVision generates the majority of company revenue through the sale of soft contact lenses, including daily disposable lenses and specialty lenses for astigmatism and presbyopia. The segment competes globally in the contact lens market and emphasizes silicone hydrogel technologies, myopia management products, and manufacturing scale. CooperSurgical generates revenue from fertility solutions, genomics services, contraception and obstetrics products, and surgical medical devices used in reproductive healthcare. The company operates manufacturing, distribution, and research facilities across North America, Europe, Latin America, and Asia-Pacific.
The company maintains a broad international footprint with substantial operations outside the United States, particularly in Europe and Asia-Pacific. It controls proprietary manufacturing technologies for specialty contact lenses and reproductive healthcare devices, and it owns a portfolio of healthcare brands and laboratory services businesses. Major subsidiaries include CooperVision, CooperSurgical, and fertility-focused businesses acquired through Generate Life Sciences. The company also maintains relationships with healthcare providers, fertility clinics, and distributors globally, supporting recurring demand and long-term customer integration.
Strategic Position & Investments
The Cooper Companies has emphasized growth through acquisitions, product innovation, and geographic expansion. In vision care, the company has invested heavily in daily disposable contact lenses and myopia management solutions, particularly the MiSight lens platform, which received regulatory approvals in multiple markets and positioned the company within the growing pediatric myopia control segment. In women’s health, the company expanded its fertility and reproductive medicine capabilities through acquisitions including Generate Life Sciences, which broadened its presence in donor services, cord blood banking, and reproductive tissue services.
The company continues investing in manufacturing capacity, automation, and global supply chain infrastructure to support increasing demand. Strategic priorities include expanding market share in specialty lenses, strengthening fertility-related service offerings, and growing recurring revenue streams tied to healthcare procedures and patient care. Cooper also participates in emerging healthcare technology areas tied to reproductive genetics, cryostorage services, and advanced contact lens materials. Public disclosures and investor materials indicate a continued focus on operational efficiency, premium product categories, and international market penetration.
Geographic Footprint
The Cooper Companies is headquartered in San Ramon, California, and operates globally across North America, Europe, Asia-Pacific, Latin America, and parts of the Middle East. The company derives a substantial portion of revenue from international markets, particularly through the global distribution of contact lenses and fertility-related medical products. Manufacturing and operational facilities are located in countries including the United States, the United Kingdom, Costa Rica, Hungary, Puerto Rico, and multiple Asian markets.
The company maintains extensive commercial operations across developed healthcare markets and continues expanding in emerging economies where demand for vision correction and fertility services is increasing. CooperVision has particularly strong international exposure compared with many U.S.-based medical device peers, while CooperSurgical has expanded its operational influence through fertility clinic networks, reproductive laboratory services, and healthcare provider relationships across multiple continents.
Leadership & Governance
The Cooper Companies operates under a corporate governance structure led by an executive management team and board of directors overseeing long-term growth strategy, operational execution, and regulatory compliance. The company’s leadership has emphasized innovation in healthcare technology, disciplined acquisitions, international expansion, and investment in specialty medical markets. Strategic messaging from company filings and investor communications has consistently focused on sustainable growth, market leadership in specialty categories, and operational scalability.
Key executives include:
- Al White – President and Chief Executive Officer
- Brian Andrews – Executive Vice President and Chief Financial Officer
- Dan McBride – Chief Operating Officer, CooperVision
- Holly Sheffield – President, CooperSurgical
- Jerry Warner – Executive Vice President, Global Human Resources
- Agostino Ricupati – Senior Vice President and Chief Strategy Officer
The company’s governance framework reflects standard public company oversight practices consistent with disclosures in SEC filings, including board committee supervision of audit, compensation, risk management, and corporate governance matters.